Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06644742 · ClinicalTrials.gov registry record

PKP2-ACM Natural History Study

A clinical trial of Cardiovascular Diseases and Heart Diseases, sponsored by Rocket Pharmaceuticals.

Recruiting
Registry status
36
Enrollment target
3
Study locations

NCT06644742 is a study of Cardiovascular Diseases and Heart Diseases that is actively recruiting participants, run by Rocket Pharmaceuticals. The registered enrollment target is 36 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06644742, a study of Cardiovascular Diseases and Heart Diseases, is actively recruiting participants, sponsored by Rocket Pharmaceuticals.

RECRUITING
Registry status
36 participants
Enrollment target
3
Study locations

Study Summary

The goal of this study is to describe the natural history and clinical events for patients who have Arrhythmogenic Cardiomyopathy with Pathogenic Plakophilin-2 Variants (PKP2-ACM) managed with standard of care.

Study Locations (3)

Massachusetts

  • Boston Children's Hospital - Boston

North Carolina

  • Duke University - Durham

Other

  • Amsterdam UMC - Amsterdam

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2026-03
Est. Completion 2031-04

Sponsor

Rocket Pharmaceuticals

10 total trials

What the Registry Record Tells You About NCT06644742

The ClinicalTrials.gov registry entry for NCT06644742 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Rocket Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT06644742 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, North Carolina, Other.

Frequently Asked Questions

What is clinical trial NCT06644742 about?

NCT06644742 is a clinical study titled "PKP2-ACM Natural History Study". The goal of this study is to describe the natural history and clinical events for patients who have Arrhythmogenic Cardiomyopathy with Pathogenic Plakophilin-2 Variants (PKP2-ACM) managed with standard of care.

What is the current status of trial NCT06644742?

This trial is currently recruiting. The enrollment target is 36 participants. The study started on 2026-03. Estimated completion is 2031-04.

What conditions does trial NCT06644742 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Heart Diseases, Cardiomyopathies, Genetic Diseases.

Who is sponsoring clinical trial NCT06644742?

This trial is sponsored by Rocket Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06644742 being conducted?

This trial has 3 study locations across Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.